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Abstract
Adrenocortical carcinomas (ACCs) are rare tumors with scant treatment options for which 
new treatments are required. The mTOR pathway mediates the intracellular signals of 
several growth factors, including the insulin-like growth factors (IGFs), and therefore 
represents a potential attractive pathway for the treatment of several malignancies 
including ACCs. Several mTOR inhibitors, including sirolimus, temsirolimus and everolimus, 
have been clinically developed. This review summarizes the results of the studies 
evaluating the expression of the mTOR pathway components in ACCs, the effects of the 
mTOR inhibitors alone or in combination with other drugs in preclinical models of ACCs 
and the early experience with the use of these compounds in the clinical setting. The 
mTOR pathway seems a potential target for treatment of patients with ACC, but further 
investigation is still required to define the potential role of mTOR inhibitors alone or in 
combination with other drugs in the treatment of ACC patients.
Introduction
Adrenocortical carcinomas (ACCs) are rare tumors with 
scant treatment options for which new treatments are 
required (1, 2, 3). The limited efficacy of conventional 
antineoplastic treatment in ACCs increases the need 
for novel effective treatment options. During the past 
15 years, progress in understanding the pathogenesis 
of tumors has encouraged the development of so-called 
‘targeted drugs’, which are compounds that specifically 
interfere with molecular mechanisms involved in tumor 
cell growth and/or tumor vascular supply, leading to 
major advances in oncology (4, 5).
Targeted drugs include compounds interfering 
with growth factor receptors and their related signaling 
pathways. Mammalian target of rapamycin (mTOR) is a 
protein kinase of the phosphoinositide 3 kinase (PI3Ks)/
protein kinase B (PKB or AKT) signaling pathway, which 
forms multimolecular intracellular complexes and 
functions as a gatekeeper of metabolism, as well as cell 
growth. mTOR receives signals from sensors of cell stress, 
intracellular nutrient levels and several growth factors, 
including vascular endothelial growth factor (VEGF), 
insulin-like growth factors (IGFs), epidermal growth factor 
(EGF) and platelet-derived growth factor (PDGF) (6, 7, 8, 
9). mTOR can be part of the two functional complexes 
mTORC1 and mTORC2. Upon the binding of several 
growth factors to their cognate tyrosine kinase receptors, 
AKT is phosphorylated and activated, which in turn 
leads to the activation of mTOR as part of the mTORC1 
complex. Activated mTORC1 complex regulates cell 
proliferation via the activation of mRNA translation and 
is mediated mainly via two downstream components, i.e. 
p70 ribosomal protein S6 kinase 1 (S6K1) and eukaryotic 
translation initiation factor 4E binding proteins (4EBP1). 
A more extensive description of this pathway has been 
previously reported and a schematic representation of the 
pathway is shown in Fig. 1 (10, 11, 12, 13). The mTORC2 
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complex regulates cytosketeton function and seems to 
be involved in the activation of AKT function (10, 11). 
Several drugs inhibiting the mTORC1 complex have been 
developed as anticancer treatment including sirolimus, 
temsirolimus and everolimus (traditional mTOR 
inhibitors), which have been approved for the treatment 
of different malignancy such as renal cell carcinoma and 
pancreatic neuroendocrine tumors (14, 15). More recently 
some compounds which also target the mTORC2 complex 
have been proposed as anticancer treatment (i.e. OSI-027, 
AZD2014) (10, 11). Alterations of growth factors and their 
cognate receptors are considered to be involved in the 
pathogenesis of ACCs (16, 17, 18, 19, 20, 21). Therefore, 
compounds interfering with tumor angiogenesis and 
growth factor signaling pathways represent a potential 
novel treatment option for the management of patients 
with ACCs. The mTOR pathway, being involved in both 
these processes, could represent a potential target for 
treatment of these malignancies (2, 22). Moreover, the 
most common molecular alteration observed in ACCs 
is the increased expression of IGF2 mRNA, which is 
reported in up to 90% of cases (22). Therefore, IGF2 has 
been suggested to be involved in the pathogenesis of 
ACCs and represents a potential target for treatment in 
this malignancy. Since the mTOR pathway is one of the 
main mediators of the intracellular effects of IGFs, the 
study of the mTOR pathway in ACCs has been considered 
attractive as potential target for treatment and to better 
understand the pathogenesis of these tumors (10).
This review aims at summarizing the results of the 
studies evaluating the expression of the mTOR pathway 
components in ACCs, the effects of the mTOR inhibitors 
alone or in combination with other drugs in preclinical 
models of ACCs and the early experience with the use 
of these compounds in the clinical setting. Our research 
group largely contributed to the current knowledge on 
the subject.
The mTOR pathway in normal adrenals
In the normal adrenal gland, a layer-specific protein 
expression pattern of the major components of the mTOR 
pathway has been found, suggesting a uncharacterized 
role of the mTOR pathway in particular adrenal 
functions. For example, the stronger expression of several 
components (i.e total-mTOR, total-/phospho-4EBP1 
and total-/phospho-S6K1) of the mTOR pathway in the 
zona reticularis could suggest a role of this pathway in 
androgen production, and the stronger expression of these 
components in the zona glomerulosa may be related to 
angiotensin II-induced activation of the mTOR pathway 
(23). An anti-secretory effect (e.g. inhibition of cortisol 
production) of mTOR inhibitors in ACC cell lines has been 
reported (24), although up to date, signs or symptoms 
of hypoadrenalism with the use of mTOR inhibitors in 
the clinical setting have not been clearly described (14). 
Further studies are required to clarify the specific role of 
the mTOR pathway in regulating steroid production.
Expression of the main components of the 
mTOR pathway in adrenocortical tumors
The expression of the main components of the mTOR 
pathway in adrenocortical tumors (ACTs) has been 
Figure 1
Schematic representation of the potential molecular pathways 
representing potential targets for treatment in patients with ACC, based 
on the results presented in the current review. GFs, growth factors; GFR, 
growth factor receptor. Brown lines show two potential escape pathways 
to the treatment with mTOR inhibitors: AKT and ERK activation.
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investigated in few studies (10, 25, 26, 27). Only one 
study evaluated the mRNA expression of mTOR, S6K1 and 
4EBP1in a cohort of ACCs, demonstrating that the mRNA 
expression of S6K1 was significantly lower in ACCs than 
in benign ACTs (adrenocortical adenomas (ACAs)) (28). A 
highly variable protein expression of the main components 
of the mTOR pathway has been described in ACCs, and 
phospho-mTOR, phospho-S6K1 as well as phospho-4EBP1 
were reported to be significantly expressed in 10–32, 
30–59 and 40–60% of cases respectively (25, 26, 28). This 
is summarized in Table 1. In the study by Nakamura et al., 
the mean protein expression of several components of 
the mTOR pathway was lower in ACC samples than in 
ACA or normal adrenal samples, although the statistics 
were not reported (26). Similarly in a study from our 
group, the protein expression of total and phospho-
mTOR, total and phospho-S6K1 and total and phospho-
4EBP1 was lower in ACCs compared to ACAs, although 
this difference was statistically significant only for total 
S6K1, and probably due to the small sample size (28). 
Even though these studies adopted different antibodies 
and methodologies, they all reported that the expression 
of the main phospho-proteins of the mTOR pathway are 
not constantly found in these tumors, suggesting that this 
pathway is activated only in a subgroup ACCs. These data 
are partially in contrast with the study by Doghman et al. 
who reported that mTOR signaling is active in childhood 
ACTs (29). These contrasting data further support the 
increasing body of evidence which suggests that adult 
ACCs and childhood ACTs are different entities. Based on 
these data, the mTOR pathway should not be expected to 
be widely involved in the pathogenesis of ACCs but might 
be involved in a subset of them.
Two studies investigated the potential prognostic 
value of the expression of some components of the 
mTOR pathway in ACTs (Table 1). We showed that 
S6K1 mRNA and protein expression are lower in ACCs 
than in ACAs, and ACC samples with a lower phospho-
S6K1 and/or phospho-4EBP1 protein expression had a 
significantly higher Weiss score than others. Additionally 
ACCs with a higher mitotic count (>5) presented a lower 
total S6K1 and phospho-4EBP1 protein expression (28). 
Recently Germano et  al. observed a negative phospho-
mTOR staining in tumors with high Weiss score (25). 
In childhood ACTs, generally known to have a less 
aggressive phenotype than adult ACCs, Doghman  et  al. 
reported a positive expression of some components of 
mTOR pathway (29). These data suggested that a subset 
of less differentiated ACCs could have an inactivation of 
the mTOR pathway. Therefore, the downregulation of the 
mTOR pathway in ACCs warrants further investigation as 
a potential prognostic factor.
In the era of personalized medicine, the description 
of the main components of the mTOR pathway in 
ACCs is an important step to explore, as their presence 
can be considered as potential markers for treatment 
with mTOR inhibitors. Considering that molecular 
biomarkers capable to predict the clinical response to 
mTOR inhibitors have not been clearly identified yet, 
the currently available studies suggest that a subset of 
patients have potential molecular evidence of mTOR 
pathway activation. However, further studies are required 
to explore whether these molecular events could predict 
an increased sensitivity to mTOR inhibitors.
Effects of mTOR inhibitors in ACCs
The testing of mTOR inhibitors in preclinical models 
of ACCs is a mandatory step to explore whether these 
compounds could represent a novel treatment opportunity 
for the management of ACCs. Few studies have evaluated 
the effects of different mTOR inhibitors, sirolimus, 
everolimus and/or temsirolimus on human ACC cancer 
cell lines (NCI-H295R, their clone HAC15 and SW13) and 
primary ACC cell cultures. Using different methodologies 
(Table 2), it was demonstrated that mTOR inhibitors 
inhibit the proliferation in ACC cell lines (including NCI-
H295R) (22, 24, 25, 28, 29, 30, 31). These compounds 
had stronger anti-proliferative effects in the SW13 cell 
line than in NCI-H295R (25, 28, 29) and showed anti-
proliferative effects in some but not all ACC primary cell 
cultures (28, 29, 30). However, it should be considered that 
while NCI-H295R cells are well accepted as a good model 
of ACCs, a debate is still open about the appropriateness of 
SW13 cells as a model for this type of cancer (32). Taking 
into account this and the other potential limitations of 
ACC cell lines as preclinical model of ACCs, the results 
of the current studies might suggest that among ACC 
patients it could be possible to find subgroups of patients 
with a higher sensitivity to mTOR inhibitors. The anti-
proliferative effects of mTOR inhibitors in ACC cells 
seem to be associated with cell cycle inhibition and/or 
apoptosis induction, although these effects have been 
observed only at high of the concentrations tested (24, 
30). Based on current data the anti-proliferative effects of 
mTOR inhibitors at concentrations that are potentially 
reachable in vivo seem to be predominantly cytostatic 
(24). An anti-secretory effect of sirolimus in ACC cells 
has also been reported (24). In mice, the inhibition of 
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Author
 
 
 
Number 
of ACCs
 
 
 
 
Methodology
 
 
 
 
Type of antibodies
 
 
Phospho-Akt: 
positive ACC 
cases (%)
 
 
mTOR: 
positive ACC 
cases (%)
 
 
Phospho-
mTOR: positive 
ACC cases (%)
 
p70 S6 
Kinase: 
positive ACC 
cases (%)
 
Phoapho-p70 
S6 Kinase: 
positive ACC 
cases (%)
Phospho-S6 
Ribosomal 
Protein: 
positive ACC 
cases (%)
 
 
4E-BP1: 
positive ACC 
cases (%)
 
 
Phospho-4E-BP1: 
positive ACC 
cases (%)
 
 
Phospho-Raptor:  
positive ACC 
cases (%)
Comparison with 
ACA
 
 
 
Comparison 
with NA
 
 
 
Consideration 
on prognosis
Nakamura 
et al. (26)
41 Standard IHC procedure. 
Specimens were 
categorized into six groups 
(0, 0%; 1, 1–5%; 2, 6–25%; 3, 
26–50%; 4, 51–75%; 5, 
76–100%).
Phospho-Akt (Ser473) 
monoclonal; phospho-
mTOR (Ser2448) 
polyclonal; Phoapho-p70 
S6 Kinase (Thr389) 
monoclonal; Phospho-S6 
Ribosomal Protein 
(Ser240/244) polyclonal; 
Phospho-4E-BP1(Thr70) 
polyclonal
Not reported Not evaluated Not reported Not evaluated Not reported Not reported Not evaluated Not reported Not evaluated With the exception 
of phospho-Akt, all 
the evaluated 
proteins were 
found to have a 
mean expression 
tendentially lower 
in ACC than in ACA, 
although the 
significance is not 
reported
All the evaluated 
proteins were 
found to have a 
mean expression 
tendentially 
lower in ACC 
than in NA, 
although the 
significance is 
not reported
Not reported
De Martino 
et al. (28)
20 Standard IHC procedure. The 
score was calculated by the 
sum of the intensity score 
and the proportion of the 
stained cells; this provided 
a score between 0 and 6. 
The proportion score was 
as follows: 0 = no positivity 
(or <10%); +1 ≤ 1/3 tumor 
cell positivity; +2 = 1/3–2/3 
tumor cell positivity; and 
+3 = more than 2/3 tumor 
cell positivity. The intensity 
score was as follows: +1 
weak staining; +2 
intermediate staining; and 
+3 strong staining. The 
score 0 was considered as 
negative, 2–3 as low, 4–5 as 
intermediate, and 6 as high. 
Finally, adrenocortical 
tumors were dichotomously 
grouped as having 
intermediate to high 
expression of the evaluated 
protein and 
phosphoproteins (IHC score 
≥4) or not (IHC score <4). 
The reported percentages 
of positive ACC cases refer 
to the percentage of cases 
having intermediate to high 
expression of the evaluated 
proteins.
mTOR monoclonal; 
Phospho-mTOR 
(Ser2448) monoclonal; 
p70 S6 Kinase 
monoclonal; 
Phoapho-p70 S6 Kinase 
(Thr389) monoclonal; 
4E-BPl monoclonal; 
Phospho-4E-BPl(Ser65) 
monoclonal
Not evaluated 60 10 25 30 Not evaluated 75 60 Not evaluated All the evaluated 
proteins were 
found to have a 
mean expression 
tendentially lower 
in ACC than in ACA. 
This difference was 
significant only for 
p70 S6 Kinase 
(P = 0.009)
Not evaluated In ACC group, a 
higher p70 S6 
Kinase 
(P = 0.04) and 
phospho-4EBP1 
(P = 0.04) 
protein 
expression 
were observed 
in tumors 
having a mitotic 
count <5
Germano  
et al. (25) 
 
 
 
 
 
 
 
58 
 
 
 
 
 
 
 
 
Tissue microarrays. Staining 
was assessed for all but 
one antibodies, using a 
binary scoring system 
based on the evaluation of 
cytoplasmic/membrane 
staining: score 0 = no 
staining, score 1 = positive 
staining. 
Phospho-Akt (Ser473) 
polyclonal; phospho-
mTOR (Ser2448) 
monoclonal; 
phospho-p70 S6K 
(Thr389) monoclonal; 
phospho-4EBP1 
(Thr37/46) polyclonal; 
phospho-Raptor 
(Ser792) polyclonal
55 
 
 
 
 
 
 
 
 
Not evaluated 
 
 
 
 
 
 
 
 
32 
 
 
 
 
 
 
 
 
Not evaluated 
 
 
 
 
 
 
 
 
59 
 
 
 
 
 
 
 
 
Not evaluated 
 
 
 
 
 
 
 
 
Not evaluated 
 
 
 
 
 
 
 
 
40 
 
 
 
 
 
 
 
 
29 
 
 
 
 
 
 
 
 
Not evaluated 
 
 
 
 
 
 
 
 
Not evaluated 
 
 
 
 
 
 
 
 
Phosho-mTOR 
expression was 
negative in 
tumors with 
high Weiss 
score 
(P = 0.025), and 
in all oncocytic 
ACC cases 
Table 1 Studies reporting the protein expression (evaluated by immunohistochemistry) of the main components of the mTOR 
pathway in adrenocortical tumors. ACA, adrenocortical adenomas; ACC, adrenocortical carcinomas; IHC, immunohistochemistry; 
NA, normal adrenals.
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positive ACC 
cases (%)
 
 
mTOR: 
positive ACC 
cases (%)
 
 
Phospho-
mTOR: positive 
ACC cases (%)
 
p70 S6 
Kinase: 
positive ACC 
cases (%)
 
Phoapho-p70 
S6 Kinase: 
positive ACC 
cases (%)
Phospho-S6 
Ribosomal 
Protein: 
positive ACC 
cases (%)
 
 
4E-BP1: 
positive ACC 
cases (%)
 
 
Phospho-4E-BP1: 
positive ACC 
cases (%)
 
 
Phospho-Raptor:  
positive ACC 
cases (%)
Comparison with 
ACA
 
 
 
Comparison 
with NA
 
 
 
Consideration 
on prognosis
Nakamura 
et al. (26)
41 Standard IHC procedure. 
Specimens were 
categorized into six groups 
(0, 0%; 1, 1–5%; 2, 6–25%; 3, 
26–50%; 4, 51–75%; 5, 
76–100%).
Phospho-Akt (Ser473) 
monoclonal; phospho-
mTOR (Ser2448) 
polyclonal; Phoapho-p70 
S6 Kinase (Thr389) 
monoclonal; Phospho-S6 
Ribosomal Protein 
(Ser240/244) polyclonal; 
Phospho-4E-BP1(Thr70) 
polyclonal
Not reported Not evaluated Not reported Not evaluated Not reported Not reported Not evaluated Not reported Not evaluated With the exception 
of phospho-Akt, all 
the evaluated 
proteins were 
found to have a 
mean expression 
tendentially lower 
in ACC than in ACA, 
although the 
significance is not 
reported
All the evaluated 
proteins were 
found to have a 
mean expression 
tendentially 
lower in ACC 
than in NA, 
although the 
significance is 
not reported
Not reported
De Martino 
et al. (28)
20 Standard IHC procedure. The 
score was calculated by the 
sum of the intensity score 
and the proportion of the 
stained cells; this provided 
a score between 0 and 6. 
The proportion score was 
as follows: 0 = no positivity 
(or <10%); +1 ≤ 1/3 tumor 
cell positivity; +2 = 1/3–2/3 
tumor cell positivity; and 
+3 = more than 2/3 tumor 
cell positivity. The intensity 
score was as follows: +1 
weak staining; +2 
intermediate staining; and 
+3 strong staining. The 
score 0 was considered as 
negative, 2–3 as low, 4–5 as 
intermediate, and 6 as high. 
Finally, adrenocortical 
tumors were dichotomously 
grouped as having 
intermediate to high 
expression of the evaluated 
protein and 
phosphoproteins (IHC score 
≥4) or not (IHC score <4). 
The reported percentages 
of positive ACC cases refer 
to the percentage of cases 
having intermediate to high 
expression of the evaluated 
proteins.
mTOR monoclonal; 
Phospho-mTOR 
(Ser2448) monoclonal; 
p70 S6 Kinase 
monoclonal; 
Phoapho-p70 S6 Kinase 
(Thr389) monoclonal; 
4E-BPl monoclonal; 
Phospho-4E-BPl(Ser65) 
monoclonal
Not evaluated 60 10 25 30 Not evaluated 75 60 Not evaluated All the evaluated 
proteins were 
found to have a 
mean expression 
tendentially lower 
in ACC than in ACA. 
This difference was 
significant only for 
p70 S6 Kinase 
(P = 0.009)
Not evaluated In ACC group, a 
higher p70 S6 
Kinase 
(P = 0.04) and 
phospho-4EBP1 
(P = 0.04) 
protein 
expression 
were observed 
in tumors 
having a mitotic 
count <5
Germano  
et al. (25) 
 
 
 
 
 
 
 
58 
 
 
 
 
 
 
 
 
Tissue microarrays. Staining 
was assessed for all but 
one antibodies, using a 
binary scoring system 
based on the evaluation of 
cytoplasmic/membrane 
staining: score 0 = no 
staining, score 1 = positive 
staining. 
Phospho-Akt (Ser473) 
polyclonal; phospho-
mTOR (Ser2448) 
monoclonal; 
phospho-p70 S6K 
(Thr389) monoclonal; 
phospho-4EBP1 
(Thr37/46) polyclonal; 
phospho-Raptor 
(Ser792) polyclonal
55 
 
 
 
 
 
 
 
 
Not evaluated 
 
 
 
 
 
 
 
 
32 
 
 
 
 
 
 
 
 
Not evaluated 
 
 
 
 
 
 
 
 
59 
 
 
 
 
 
 
 
 
Not evaluated 
 
 
 
 
 
 
 
 
Not evaluated 
 
 
 
 
 
 
 
 
40 
 
 
 
 
 
 
 
 
29 
 
 
 
 
 
 
 
 
Not evaluated 
 
 
 
 
 
 
 
 
Not evaluated 
 
 
 
 
 
 
 
 
Phosho-mTOR 
expression was 
negative in 
tumors with 
high Weiss 
score 
(P = 0.025), and 
in all oncocytic 
ACC cases 
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NCI-H295R xenograft growth has been reported using 
high everolimus dose (29). Additionally, sirolimus was 
found to significantly reduce cell survival and cortisol 
secretion only in selected ACC primary cultures (28). These 
data suggest that a subset of patients with ACCs might be 
more sensitive than others to this treatment. Therefore, 
further studies are warranted to find potential biomarkers 
predictive of response to treatment with mTOR inhibitors 
in ACCs. In this respect, the protein expression of the 
main components of the mTOR pathway was investigated 
in relation to the in vitro effects of mTOR inhibitors in 
ACC primary cultures (28). However, the expression of 
none of the evaluated proteins correlated with the in vitro 
response to these drugs (28). This absence of a correlation 
could be due to the low number of primary cultures used 
in this study. However, specifically designed clinical trials 
can appropriately evaluate for biomarkers predictive of 
response to treatments. Unfortunately, this type of clinical 
trials is extremely difficult to perform in such a rare 
cancer as ACCs. Therefore, progress in this direction can 
only be awaited from the results of clinical trials in other 
more common types of cancer. Once a clear predictive 
biomarker is identified in other cancers, its value in ACCs 
should be explored.
To the best of our knowledge, the effects of compounds 
targeting the mTORC1 and 2 complex in ACC cell lines 
have not been explored yet. A recent study reported that 
n-3 polyunsaturated fatty acids prevent ACC growth by 
inhibiting mTORC1/2 in preclinical models of ACCs, 
which suggests that both mTORC complexes might play 
a role in ACC cell proliferation (33). Another compound 
that was reported to inhibit ACC growth in preclinical 
models of ACCs is the dual PI3-kinase/mTOR inhibitor 
NVP-BEZ235 (34). These new class of compounds require 
future investigations.
Relationship between the mTOR and the IGF 
pathways in ACCs
The relationship between the mTOR and the IGF 
pathways in ACCs has been scantly investigated (10). 
As the mTOR pathway mediates some of the IGF effects 
(10, 35, 36), it could be involved in mediating the pathogenic 
effects of IGFs in ACCs. Therefore it might be important 
to understand whether a differential expression of the 
main components of the IGF pathway could influence the 
in vitro sensitivity to mTOR inhibitors and whether there 
is a rational to combine drugs targeting the IGF and the 
mTOR pathways.Au
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The relationship between the mTOR- and the IGF 
pathways in the NCI-H295R and SW13 ACC cell lines 
is addressed in a few studies (24, 28). These studies 
demonstrate that both ACC cell lines have a similar 
protein expression of IGF1R and the main components 
of the mTOR pathway, but both mRNA and protein 
expression of IGF2 were considerably higher in NCI-H295R 
compared with SW13. IGF1 significantly stimulated AKT 
and S6K1 phosphorylation in both NCI-H295R and 
SW13, demonstrating that the mTOR pathway acts as an 
intracellular mediator of IGFs in both human ACC cell 
lines (24). A schematic representation of the pathway 
is shown in Fig. 1. Therefore, the mTOR pathway could 
also be involved in mediating the proliferative effects of 
IGFs in ACC cell lines. However, the effects of the mTOR 
inhibitor sirolimus on the IGF-activated intracellular 
pathways were different between NCI-H295R and 
SW13 cells. At the experimental condition tested, IGF1 
induced the activation of the AKT/mTOR pathway in 
both cell lines, but ERK activation was observed only in 
NCI-H295R. Sirolimus efficiently suppressed the mTORC1 
activity in both cell lines. However, only in NCI-H295R 
cells, the inhibition of mTORC1 activity was associated 
with the activation of AKT, likely representing an escape 
pathway. This activation was further enhanced by IGF1 
administration which also induced ERK stimulation in 
the sirolimus-treated NCI-H295R cells. Therefore, the 
NCI-H295R cell line seems to have two potential pathways 
of escape to treatment with traditional mTOR inhibitors: 
the AKT and ERK pathways (see Fig. 1 for the potential 
escape pathways) (35, 37). The activation of these escape 
pathways could be related, at least partially, to the IGF2 
overexpression in NCI-H295R, which is not found in the 
SW13 cell model. Therefore, it could be speculated that 
high IGF2 expression could negatively influence the 
in vitro sensitivity of ACC cell lines to mTOR inhibitors, 
which supports the rationale to combine mTOR inhibitors 
and drugs specifically targeting the IGF pathway in ACCs 
(31). In another study everolimus has been reported to 
inhibit S6K1 phosphorylation in both NCI-H295R and 
SW13, to only slightly reduce AKT phosphorylation at the 
highest drug concentration used and to have no effect on 
ERK phosphorylation (30). High everolimus doses might 
reduce AKT phosphorylation sequestering of the mTOR as 
part of the mTORC1 complex and subsequently inhibiting 
the mTORC2 activity (10).
IGF2 overexpression is very common in ACC (about 
80%) (18), whereas only a subset of ACC samples strongly 
expressed the components of the mTOR pathway, 
particularly the phospho-proteins (28). In the studies 
from our research group a subgroup of 16 ACC samples 
was characterized for protein expression of the main 
components of both mTOR and IGF pathway, including 
IGF2 (28, 31). Within this subgroup of ACC samples, we 
were not able to find correlations between these proteins 
(Table 3; personal unpublished data). Therefore, the 
expression of the main components of the mTOR and the 
IGF pathways seem not to be strongly related, which raises 
the questions whether in ACCs there is a dissociation 
between the expression of IGF2 and the activation of 
the classical IGF stimulated intracellular pathways, and 
whether the role of IGF2 in the pathogenesis of adult 
ACCs may have been overestimated, in agreement with 
some other recent speculations (38). However, it should 
also be considered that the complexity of the IGF system 
may have been underestimated since ACC expresses 
other components of the IGF pathway as well, such as 
the insulin receptor subtype A and the IGF2R (31, 36). 
These components have been scantly considered up 
today. As such, before finally declaring a ‘game over’ (38) 
for the role of IGF2 in adrenocortical tumorigenesis and 
as a potential target for novel treatment in ACC patients, 
it could be probably useful to return to the bench and 
try to better explore the IGF pathway in ACCs in its 
whole complexity.
Effects of mTOR inhibitors in combination 
with other drugs in ACTs
The data derived from the use of the mTOR inhibitors 
alone in preclinical studies (24, 25, 28-30), together 
with the expected heterogeneity of ACCs (25, 28, 39), 
suggest that caution is required before using this class of 
drugs in unselected ACC patients. Such caution was also 
suggested by preliminary clinical experience with the use 
of everolimus in some ACC patients with a late stage of 
disease (40). Unfortunately, due to the current lack of 
molecular biomarkers capable to predict the response to 
mTOR inhibitors in ACCs (25, 28), it is difficult to define 
selection criteria for ACC patients that are candidate for 
treatment with this class of drugs. Therefore, combination 
of mTOR inhibitors with other drugs, potentially active 
in ACCs, could be a more prudent clinical approach than 
the use of these inhibitors as monotherapy in unselected 
ACC patients.
Until recently, the IGF pathway was considered as 
the most attractive target for new treatment in ACCs 
(10, 41, 42) with a potential rationale to combine mTOR 
inhibitors with drugs targeting the IGF pathway (11, 24). 
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Linsitinib (OSI-906) is an IGF1-R/insulin receptor blocker 
that has recently been tested in a phase III trial in 
ACC patients (43). It was shown that only a very small 
subgroup of patients seems to benefit from treatment 
with this drug, but the anticipated improvement in 
overall or progression-free survival was not observed. 
This observation again illustrates that ACCs is a very 
heterogenous disease. However, whether combining 
drugs that target the IGF system with other compounds, 
such as mTOR inhibitors, could be more effective requires 
further investigation. A recent study explored the in vitro 
effects of mTOR inhibitors in combination with linsitinib 
and showed that, particularly when cells were cultured in 
medium with low serum, combined treatment of mTOR 
inhibitors with linsitinib has additive growth inhibitory 
effects on ACC cells at pharmacological concentrations 
(31). This supports a potential role for treatment strategies 
combining mTOR inhibitors and drugs targeting the IGF 
pathway in ACCs. These results are in line with a recently 
published phase I study demonstrating that a subgroup 
(about 40%) of ACC patients treated with cixutumumab 
(IGF1R inhibitor) and temsirolimus (mTOR inhibitor) 
experienced long-term disease stabilization (longer than 
6 months) (44).
Another attractive candidate for new combination 
treatment strategies in ACCs is mitotane, since this drug 
is currently considered as a key drug in the treatment of 
patients with advanced ACCs. Unfortunately the majority 
of studies suggest that about two-thirds of patients do 
not respond and/or do not tolerate this drug (1, 45, 46, 
47). In ACC cell lines, two studies reported the effects of 
mTOR inhibitors in combination with mitotane (22, 25). 
One study demonstrated that sirolimus had some additive 
effects with mitotane, but only when mitotane was used 
at low concentration (22), whereas another study reported 
that mitotane blocked the anti-proliferative effects of 
everolimus (25). Although these studies are contrasting 
in their main final conclusions, both studies show that 
the effects of mitotane can, at least in some conditions, 
overcome the effects of the mTOR inhibitors thus limiting 
the usefulness of combining full doses of these two 
therapeutic agents. As mentioned earlier, the preclinical 
results show that the addition of sirolimus to low 
concentrations of mitotane has stronger anti-proliferative 
effects than mitotane alone (22). If these results could be 
translated to humans, they suggest that the addition of 
sirolimus might add to the antitumor action of mitotane, 
thereby reducing the mitotane dose required to obtain a 
desired clinical effect with potentially fewer side effects. 
In a clinical setting, mTOR inhibitors can be metabolized Ta
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by the microsomal liver enzyme cytochrome P450 
(CYP3A4/5). Drugs as mitotane are capable to induce these 
enzymes, and might increase the liver metabolization 
of mTOR inhibitors, potentially reducing the plasma 
concentration of these compounds to sub-therapeutic 
levels (44, 48). The combination of the mTOR inhibitor 
everolimus and the tyrosine kinase inhibitor sorafenib has 
been evaluated in preclinical models of ACCs in which 
it is shown that combined treatment was more effective 
than single drug treatment both in ACC cell lines and in 
xenograft models. These data support the rationale for 
combined treatment in this type of malignancy (30).
New potential targets for ACCs in addition to 
the IGF and mTOR pathways
Until today, most of the early clinical experience with 
targeted drugs, including drugs targeting the IGF pathway, 
failed to demonstrate the desired effects in patients 
with ACCs (2, 38, 43). This raises the question whether 
molecular events, potentially targetable with currently 
developed drugs, are present in at least a subset of ACC 
patients. Using hotspot gene sequencing and comparative 
genomic hybridization, the presence of a large number of 
mutations and copy number abnormalities of potential 
interest for therapeutic aims, were evaluated in a large 
group of adult ENSAT stage III-IV ACC samples. No relevant 
alteration in the evaluated components of the mTOR 
and IGF pathways were found with these techniques 
and no simple targetable molecular event emerged (21, 
39). Therefore, based on genomic alterations, the cell 
cycle appeared to be the most relevant new potential 
therapeutic target for patients with advanced ACC (Fig. 
1). Recent data from exome sequencing confirm that the 
cell cycle or WNT pathways might be future target for 
treatment in ACCs (20, 49). Further studies to explore the 
effects of these compounds in preclinical models of ACCs 
are warranted.
Overall current data underline that, despite the fact 
that during the last 10 years much progress has been 
made in describing the molecular alteration in ACCs, the 
translation of these progress from bench to the bedside 
with the aim to improve the treatment of patients with 
ACCs has not been easy, so far.
Conclusion and future directions
In conclusion, the mTOR pathway seems a potential 
target for treatment of a subset of patients with ACCs, 
but treatment strategies combining mTOR inhibitors with 
other drugs are expected be more effective than the use 
of mTOR inhibitors alone. Additionally, considering the 
potential heterogeneity of this malignancy, treatment 
strategies based on the selection of patients with a 
potentially higher chance to respond to mTOR inhibitors 
according to their tumor characteristics, might be more 
effective than the use of mTOR inhibitors in unselected 
patients. Unfortunately, molecular biomarkers capable to 
predict a clinical response to mTOR inhibitors have not 
been clearly identified yet. Therefore, further preclinical 
and clinical investigations are required to find new 
molecular biomarkers useful to predict tumor response to 
both conventional and novel treatments for patients with 
ACCs and to address the role of mTOR inhibitors, alone 
or in combination with other drugs, in selected subgroups 
of patients with these tumors. All these data could help to 
move into the direction of a more personalized approach 
to the treatment of ACCs, and hopefully this approach 
could lead to progress in the clinical management of this 
rare but aggressive disease.
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